Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQH2722
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
TQH2722 is a **humanized monoclonal antibody** targeting the interleukin 4 receptor alpha (IL4Rα) subunit. It blocks the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), inhibiting the T-helper cell type 2 immune pathway. This mechanism is beneficial for treating diseases like atopic dermatitis, asthma, and chronic sinusitis. Developed by Biosion and CTTQ, it is administered via subcutaneous injection.
- Other names
- TQH-2722TQH2722TQH 2722
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on TQH2722.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQH2722.